Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Clin Cancer Res. 2016 Oct 19;23(7):1771–1784. doi: 10.1158/1078-0432.CCR-16-1317

Figure 2. Down-regulation of STAT3 and STAT3 targets by AZD9150 treatment in vitro.

Figure 2

A. STAT3 mRNA expression in neuroblastoma cell lines treated with AZD9150 (0.25, 0.5, 1, 2.5, 5, 10 µM) or ntASO (10 µM) for 6 days was validated by qPCR. The data is presented as the mean of 3 replicate tests ± SE. *, P<0.05 was indicated for AZD9150 treated cells vs. control cells (t-test).

B. STAT3 protein expression in neuroblastoma cell lines treated with AZD9150 (0.25, 0.5, 1, 2.5, 5, 10 µM) or ntASO (10 µM) for 6 days was validated by Western blotting. Ratios of T-STAT3/GAPDH shown under the representative blots were normalized to that of untreated-control (normalized as “1”) in each cell line.

C. STAT3 target mRNA expression in neuroblastoma cell lines treated with AZD9150(1 µM) or ntASO (1 µM) for 6days was validated by qPCR. The data is presented as the mean of 3 replicate tests ± SE. *, P<0.05 was indicated for AZD9150 treated cells vs. ntASO treated cells (t-test).

D. STAT3 target protein expression in neuroblastoma cell lines treated with AZD9150(1 µM) or ntASO (1 µM) for 6days was validated by Western blotting. Ratios of the detected target/GAPDH shown under the representative blots were normalized to that of untreated-control (normalized as “1”) in each cell line.